Skip to content
The Policy VaultThe Policy Vault

Danziten (nilotinib tablets – Azurity) — Cigna

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions (ABL1 rearrangement)

Initial criteria

  • Patient age ≥ 18 years
  • Tumor has an ABL1 rearrangement

Approval duration

1 year